Quotient Clinical completes successful first US FDA Inspection

Quotient Clinical is pleased to announce that it has successfully completed its first inspection by the US Food and Drug Administration (FDA). The inspection took place on 7 – 11 December 2015 and focused on a clinical bioequivalence study conducted for a Sponsor at Quotient’s clinical facility in Nottingham, UK, with no Form 483 observations issued.

Mark Egerton, Chief Executive Officer of Quotient Clinical, commented: “this positive endorsement by the FDA reinforces our commitment to high quality clinical research for a global customer base and adds to our long outstanding audit history with UK regulator the MHRA.”

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.